期刊文献+

阿片类生长因子受体假基因1靶向miR-665对卵巢癌细胞增殖、侵袭和迁移的影响 被引量:2

Opioid growth factor receptor pseudogene 1 inhibits proliferation,invasion and migration of ovarian cancer cells by targeting miR-665
原文传递
导出
摘要 目的探讨阿片类生长因子受体假基因1(OGFRP1)对卵巢癌细胞增殖、侵袭和迁移的影响及其作用机制。方法选取120例卵巢癌患者癌组织及正常卵巢组织,实时荧光定量PCR(RT-qPCR)检测OGFRP1和miR-665表达水平;将A2780细胞分为空白(PBS)组、si-NC组、si-OGFRP1组、miR-NC组、miR-665组、si-OGFRP1+anti-miR-NC组、si-OGFRP1+anti-miR-665组。四甲基偶氮唑盐比色法(MTT)检测细胞存活率;Transwell检测细胞迁移和侵袭;双荧光素酶报告实验检测OGFRP1和miR-665的靶向关系。结果与正常卵巢组织相比,卵巢癌组织中OGFRP1表达水平升高(2.75±0.27 vs 1.00±0.09),miR-665表达水平降低(0.51±0.05 vs 1.00±0.08)(均P<0.05)。抑制OGFRP1表达或过表达miR-665后,卵巢癌A2780细胞的活性、细胞迁移与侵袭数均降低(均P<0.05)。双荧光素酶报告实验结果显示,OGFRP1靶向调控miR-665;抑制miR-665和OGFRP1表达后,卵巢癌A2780细胞活性升高,迁移、侵袭细胞数增加(P<0.05)。结论抑制OGFRP1表达可抑制卵巢癌A2780细胞增殖、迁移和侵袭,其机制可能与上调miR-665有关。 Objective To investigate the effect of OGFRP1 on proliferation,invasion and migration of ovarian cancer cells and the underlying mechanism.Methods 120 pairs of cancer tissues and normal ovarian tissues from patients with ovarian cancer were included.Real-time fluorescent quantitative PCR(RT-qPCR)was used to detect the expression levels of OGFRP1 and miR-665.A2780 cells were divided into the blank(PBS)group,si-NC group,si-OGFRP1 group,miR-NC group,miR-665 group,si-OGFRP1+anti-miR-NC group,and si-OGFRP1+anti-miR-665 group.Methyl-thiazolyl tetrazolium(MTT)-based colorimetric method was used to detect cell viability;Transwell assay was used to detect cell migration and invasion;dual luciferase reporter assay was used to detect the targeting relationship between OGFRP1 and miR-665.Results Compared with normal ovarian tissue,the expression level of OGFRP1 was increased(2.75±0.27 vs 1.00±0.09),and the expression level of miR-665 was decreased(0.51±0.05 vs 1.00±0.08)(all P<0.05),in ovarian cancer tissue.After inhibiting the OGFRP1 expression or overexpressing miR-665,the viability,cell migration and invasion of ovarian cancer A2780 cells were reduced(all P<0.05).Dual luciferase report assay showed that OGFRP1 targeted and regulated miR-665.After inhibiting the expression of miR-665 and OGFRP1,the viability of ovarian cancer A2780 cells increased,and so did the number of migrating and invasive cells(P<0.05).Conclusion Suppressing the expression of OGFRP1 can inhibit the proliferation,migration and invasion of ovarian cancer A2780 cells.The underlying mechanism may be related to the up-regulation of miR-665.
作者 李芳 陈翎 王亚荣 Li Fang;Chen Ling;Wang Yarong(Department of Gynecology,Shanxi Provincial People’s Hospital,Taiyuan 030002,Shanxi,China)
出处 《中华生物医学工程杂志》 CAS 2020年第6期508-514,共7页 Chinese Journal of Biomedical Engineering
关键词 卵巢肿瘤 阿片类生长因子受体假基因1 miR-665 增殖 侵袭 迁移 ovarian neoplasms opioid growth factor receptor pseudogene 1 miR-665 proliferation invasion migration
  • 相关文献

参考文献6

二级参考文献19

  • 1Ricken A,Lochhead P,Kontogiannea M,et al.Wnt signaling in the ovary:identification and compartmentalized expression of wnt-2,wnt-2b,and frizzled-4 mRNAs[J].Endocrinology,2012,143:2741-2749.
  • 2Tanaka Y,Kobayashi H,Suzuki M,et al.Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer[J].Gynecol Oncol,2004,94:725-734.
  • 3Klaus A,Birchemeier W.Wnt signalling and its impact on development and cancer[J].Nat Rev Cancer,2008,8:387-398.
  • 4Fuerer C,Nusse R,Ten Berge D.Wnt signaling indevelopment and disease.Max Delbrtck Center for molecular medicine meeting on Wnt signaling in development and disease[J].EMBO Rep,2008,9:134-138.
  • 5Katoh M.Differential regulation of WNT2 and WNT2B expression in human cancer[J].Int J Mol Med,2001,8:657-660.
  • 6Katoh M.WNT2B:comparative integromics and clinical applications(Review)[J].Int J Mol Med,2005,16:1103-1108.
  • 7Stuart MA,Huck WT,Genzer J,et al.Emerging applications of stimuli-responsive polymer materials[J].Nat Mater,2010,9:101-113.
  • 8Blouse GE,Perron MJ,Thompason JH,et al.A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition[J].Biochemistry,2002,41:11997-12009.
  • 9Steiner E,Pollow K,Hasenclever D,et al.Role of urokinasetype plasminogen activator (uPA)and plasminogen activator inhibitor type1 (PAI-1)for prognosis in endometrial cancer[J].Gynecol Oncol,2008,108:569-576.
  • 10van der Burg ME,Henzen-Logmans SC,Berus EM,et al.Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign,borderline,malignant primary and metastatic ovarian tumors[J].IntJ Cancer,1996,69:475-479.

共引文献35

同被引文献23

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部